Of note, a recent meta-analysis showed no difference in the OR to PARP inhibition in solid tumors regardless of whether BRCA mutations were germ line or somatic in origin.39 The NOVA trial supported this hypothesis by showing that niraparib resulted in responses in ovarian cancer patients who have progressed on platinum agents. Here, PARP1 is linked to ovarian cancer.